The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.
 
Matthew H. G. Katz
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Alcresta Therapeutics
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Jeffrey P. Meyers
No Relationships to Disclose
 
Joseph M. Herman
Consulting or Advisory Role - Bristol-Myers Squibb; Sirtex Medical
Research Funding - 1140 Foundation (Inst); Augmenix (Inst); Galera Therapeutics (Inst); Stand up to Cancer (Inst)
 
Michael Choung
No Relationships to Disclose
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; GRAIL
Research Funding - Celgene; Lilly
 
Syed Ahmad
Speakers' Bureau - Abbvie
 
Robert de Wilton Marsh
Patents, Royalties, Other Intellectual Property - University of Florida (Inst)
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
Spencer Behr
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; GenVivo; More Health; Progenics
Research Funding - Cancer Targeted Technology
 
Wendy L. Frankel
Travel, Accommodations, Expenses - Ohio State University (Inst)
 
Eric Andrew Collisson
Stock and Other Ownership Interests - BloodQ; Clara Health; Guardant Health; Hint Health; Tatara Therapeutics
Consulting or Advisory Role - Merck
Research Funding - Ferro Oncology/Bridge Bio (Inst); Loxo/Bayer (Inst); Merck KGaA (Inst); Senti Biosciences (Inst)
 
James Lewis Leenstra
No Relationships to Disclose
 
Terence Marques Williams
No Relationships to Disclose
 
Gina M. Vaccaro
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Exelixis; Incyte; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - Incyte
Research Funding - Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst)
 
Alan P. Venook
Consulting or Advisory Role - Genentech; Halozyme; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Genentech; Roche
 
Jeffrey A Meyerhardt
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)